Home » Stocks » VLON

Vallon Pharmaceuticals, Inc. (VLON)

Stock Price: $5.00 USD -0.30 (-5.64%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
After-hours: $5.09 +0.09 (1.78%) Mar 5, 5:57 PM
Market Cap 34.06M
Revenue (ttm) 100,000
Net Income (ttm) -4.22M
Shares Out 6.76M
EPS (ttm) -0.63
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $5.00
Previous Close $5.30
Change ($) -0.30
Change (%) -5.64%
Day's Open 5.40
Day's Range 4.90 - 5.44
Day's Volume 72,821
52-Week Range 4.90 - 9.90

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 4 days ago

PHILADELPHIA, PA, March 03, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on th...

GlobeNewsWire - 1 week ago

- Accomplished executive leader with more than 30 years of experience in finance and operations

GlobeNewsWire - 3 weeks ago

PHILADELPHIA, PA, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON) (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the ...

GlobeNewsWire - 3 weeks ago

PHILADELPHIA, PA, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs...

NASDAQ - 1 month ago

Vallon Pharmaceuticals, a biopharma developing abuse-deterrent prescription drugs for CNS disorders, announced terms for its IPO on Thursday.

SEC - 1 month ago

Vallon Pharmaceuticals, Inc. has filed to go public with an IPO on the NASDAQ.

About VLON

Vallon Pharmaceuticals, a biopharmaceutical company, focuses on the development and commercialization of prescription drugs for central nervous system disorders. The company develops abuse-deterrent amphetamine immediate-release, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder and narcolepsy. It also develops ADMIR, an abuse deterrent formulation of Ritalin. The company was incorporated in 2018 and is based in Philadelphia, Pennsylvania.

Industry
Biotechnology
IPO Date
Feb 10, 2021
CEO
David Baker
Employees
2
Stock Exchange
NASDAQ
Ticker Symbol
VLON
Full Company Profile

Financial Performance

Financial Statements